Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC decreased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 81.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,274 shares of the company's stock after selling 54,293 shares during the period. Sherbrooke Park Advisers LLC's holdings in Amneal Pharmaceuticals were worth $97,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Barclays PLC boosted its holdings in shares of Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company's stock valued at $2,466,000 after purchasing an additional 169,756 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth $520,000. Amundi purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth $256,000. Entropy Technologies LP purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth $259,000. Finally, Principal Financial Group Inc. lifted its holdings in Amneal Pharmaceuticals by 9.3% during the fourth quarter. Principal Financial Group Inc. now owns 96,835 shares of the company's stock worth $767,000 after buying an additional 8,213 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Barclays upped their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $11.50.

Amneal Pharmaceuticals Trading Up 1.9%

Shares of AMRX stock traded up $0.14 during trading hours on Tuesday, reaching $7.30. 173,446 shares of the company's stock were exchanged, compared to its average volume of 1,447,172. The stock's 50 day moving average is $7.59 and its 200-day moving average is $8.04. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -10.73 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.29 and a fifty-two week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. This trade represents a 4.24% decrease in their position. The disclosure for this sale can be found here. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.